Dexamethasone plus Orelabrutinib for newly diagnosed immune thrombocytopenia
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests whether adding a drug called orelabrutinib to high-dose dexamethasone (a steroid) works better than dexamethasone alone for treating newly diagnosed immune thrombocytopenia (ITP)—a condition where your body destroys its own platelets, causing very low blood counts. The goal is to see if the combination helps raise your platelet count and prevents bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18–80 years old and weigh at least 35 kg (about 77 lbs)
- You have newly diagnosed ITP that has never been treated before, with platelet count below 30,000 per microliter of blood and no active bleeding in vital organs
- You recently responded well to a 4-day trial of high-dose dexamethasone (your platelets rose to at least 30,000 and doubled from baseline)
- You are not pregnant, not breastfeeding, and willing to use reliable birth control during the trial and for 90 days after your last dose
- You do not have a history of brain bleeding, HIV, active tuberculosis, blood clotting disorders, or severe organ dysfunction
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of two medicines—one that calms the immune system and one that helps your body make more platelets. It is for people with long-term ITP who have already tried other treatments and still have low platelet counts.
This trial tests a combination of romiplostim (a platelet-boosting drug) and steroids as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). It aims to see if this approach can safely and effectively raise platelet counts.
This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.
This trial compares two ways to raise platelet counts in people with immune thrombocytopenia (ITP) who did not get enough benefit from a short course of a standard medicine. One option is a higher dose of a similar medicine, and the other is switching to a different pill. The goal is to find a treatment that works better with fewer side effects.
This Phase 3 study tests whether adding an injection called belimumab (or a placebo) to rituximab works better and is safe for adults with long-lasting immune thrombocytopenia (ITP). You may be eligible if your platelet counts stay low despite prior steroid and/or IVIG treatment and if infections, vaccines, and other health conditions meet the study rules.
This trial compares two different dosing schedules of a high-dose corticosteroid called dexamethasone to see which one works better for people who have just been diagnosed with ITP (when your immune system attacks your platelets, causing low counts and bleeding). The goal is to find a treatment that raises your platelet count more effectively and safely.
Hear when a new Primary Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.